Katherine D. Cummins

Katherine D. Cummins

Auto-generated profile, based on publicly available information

Katherine D. Cummins

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MKMichael Klichinsky
Michael Klichinsky
MRMarco Ruella
Marco Ruella
OSOlga Shestova
Olga Shestova
XLXueqing Maggie Lu
Xueqing Maggie Lu
ABAndrew Best
Andrew Best
SGSaar Gill
Saar Gill

1 May 2018 in Cell
Verified
Journal Article
Closed access
MKMiriam Y. Kim
Miriam Y. Kim
Kyung-Rok YuKyung-Rok Yu
Kyung-Rok Yu
SKSaad S. Kenderian
Saad S. Kenderian
MRMarco Ruella
Marco Ruella
SCShirley Chen
Shirley Chen
SGSaar Gill
Saar Gill

21 February 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
SGSaba Ghassemi
Saba Ghassemi
JDJoseph S. Durgin
Joseph S. Durgin
SNSelene Nunez-Cruz
Selene Nunez-Cruz
JPJai Patel
Jai Patel
JLJohn Leferovich
John Leferovich
MMMichael C. Milone
Michael C. Milone

22 April 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NSNathan Singh
Nathan Singh
NFNoelle V. Frey
Noelle V. Frey
BEBoris Engels
Boris Engels
DBDavid M. Barrett
David M. Barrett
OSOlga Shestova
Olga Shestova
MRMarco Ruella
Marco Ruella

28 July 2017 in Leukemia
Verified
Journal Article
Closed access
PDF file
TTT-C Teh
T-C Teh
NNN-Y Nguyen
N-Y Nguyen
DMD M Moujalled
D M Moujalled
DSD Segal
D Segal
GPG Pomilio
G Pomilio
AWA H Wei
A H Wei

29 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YLYong Gu Lee
Yong Gu Lee
PGPuneeth Guruprasad
Puneeth Guruprasad
GGGuido Ghilardi
Guido Ghilardi
RPRaymone Pajarillo
Raymone Pajarillo
CSChristopher Tor Sauter
Christopher Tor Sauter
MRMarco Ruella
Marco Ruella
Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two thirds of patients experience treatment failure. Resistance to apoptosis is a key feature of cancer cells, and it is associated with treatment failure. In 87 patients with NHL treated with anti-CD19 CART, we found that chromosomal alteration of B-cell lymphoma 2 (BCL-2), a critical antiapoptotic regulator, in lymphoma cells was associated with reduced survival. Therefore, we combined CART19 with the FDA-approved BCL-2 inhibitor venetoclax and demonstrated in vivo synergy in venetoclax-sensitive NHL. However, higher venetoclax doses needed for venetoclax-resistant lymphomas resulted in CART toxicity. To overcome this limitation, we developed venetoclax-resistant CART by overexpressing mutated BCL-2(F104L), which is not recognized by venetoclax. Notably, BCL-2(F104L)-CART19 synergized with venetoclax in multiple lymphoma xenograft models. Furthermore, we uncovered that BCL-2 overexpression in T cells intrinsically enhanced CART antitumor activity in preclinical models and in patients by prolonging CART persistence. Significance: This study highlights the role of BCL-2 in resistance to CART immunotherapy for cancer and introduces a novel concept for combination therapies—the engineering of CART cells to make them resistant to proapoptotic small molecules, thereby enhancing the therapeutic index of these combination therapies. This article is highlighted in the In This Issue feature, p. 2221